Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

Potential combo therapy with Remdesivir:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 195
Posts 16,222
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Gilead Sciences & Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop & Co-Commercialize Next-Gener... Business Wire - 7/13/2020 4:05:00 PM
Gilead: Remdesivir Associated With Recovery, Reduction in Mortality Risk Dow Jones News - 7/10/2020 9:27:00 AM
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19 Business Wire - 7/10/2020 8:30:00 AM
Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders Business Wire - 7/8/2020 4:01:00 AM
Precision BioSciences Says Gilead Ends Hepatitis B Collaboration Dow Jones News - 7/6/2020 8:23:00 AM
Correction to Poor Performance of Health-Care Stocks Article Dow Jones News - 7/5/2020 6:43:00 PM
Coronavirus Is No Cure for Health-Care Stocks Dow Jones News - 7/5/2020 5:17:00 PM
Coronavirus Is No Cure for Health-Care Stocks Dow Jones News - 7/5/2020 8:29:00 AM
New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults Business Wire - 7/4/2020 3:01:00 AM
Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Len... Business Wire - 7/4/2020 3:01:00 AM
European Commission Authorizes Gilead's Marketing of Remdesivir for Covid-19 Treatment Dow Jones News - 7/3/2020 9:14:00 AM
European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COV... Business Wire - 7/3/2020 7:56:00 AM
Arthritis Drug Fails in Study of Covid-19 Patients Dow Jones News - 7/2/2020 6:17:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 5:04:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 4:56:35 PM
Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment & Cure Research Data P... Business Wire - 7/1/2020 8:30:00 AM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 7th Update Dow Jones News - 6/29/2020 5:23:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 6th Update Dow Jones News - 6/29/2020 4:37:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 5th Update Dow Jones News - 6/29/2020 4:24:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 4th Update Dow Jones News - 6/29/2020 4:14:00 PM
Correction to Cost of Covid-19 Drug Remdesivir Article Dow Jones News - 6/29/2020 1:34:00 PM
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance Dow Jones News - 6/29/2020 7:29:00 AM
An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences Business Wire - 6/29/2020 7:00:00 AM
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics Business Wire - 6/23/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/16/2020 6:52:28 PM
north40000 Member Level  Saturday, 05/23/20 03:23:00 AM
Re: Stowe post# 3895
Post # of 4239 
Potential combo therapy with Remdesivir:

https://www.reuters.com/article/us-health-coronavirus-haseltine-newsmake/top-hiv-scientist-says-he-wouldnt-count-on-a-vaccine-for-coronavirus-soon-idUS

....."For treatment, patients have been getting antibody-rich plasma donated by people who recovered from COVID-19, and drugmakers are at work producing refined and concentrated versions of that serum.

Known as hyperimmune globulin, those products are “where the first real treatments are going to be,” he said, predicting success also with research into monoclonal antibodies that home in on and neutralize the ability of the virus to enter human cells."

&&&&&&&&&&&&&&&&&&
GILD added Vascepa to a cohort of an oncology study months ago.

https://ih.advfn.com/stock-market/NASDAQ/amarin-AMRN/stock-news/82513921/amarin-supports-trial-to-investigate-the-effects-o


|"Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19
May 21 2020 - 04:05PM
GlobeNewswire Inc. Print

Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA®) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial is sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group and is being led by Dr. Subodh Verma MD, FRCSC, FAHA, PhD, cardiac surgeon-scientist at St. Michael's Hospital in Toronto, and professor at the University of Toronto, and Dr. Deepak L. Bhatt MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor, Harvard Medical School. The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group.
Based on our current understanding of the biological effects of a COVID-19 infection, including that patients at high risk of cardiovascular disease are at higher risk of mortality and severe effects from a COVID-19 infection, and based on data related to the mechanism of action and effects of VASCEPA in lowering cardiovascular risk in certain high-risk patients, it is believed that VASCEPA could play a beneficial clinical role in helping patients infected by the virus.


The clinical effects of VASCEPA are multi-factorial. Multiple mechanisms of action associated with VASCEPA from clinical and mechanistic studies support the rationale to study its effects in patients with the COVID-19 infection. Additional postulated mechanisms that might play a role in the use of VASCEPA in the patients infected with COVID-19 include the following:

• Potential antiviral/antimicrobial effects1
• Fibrosis and cardiac damage mitigation in animal models2,3
• Anti-inflammatory effects (acute) in pulmonary/lung tissue4,5
“We believe that this pilot study may provide important information on whether, how, and if icosapent ethyl has biological activity that could have beneficial effects in mitigating severity in COVID-19 infection. If a positive signal is achieved in this study, larger, more definitive studies could then be considered,” stated Dr. Bhatt. “This pilot will also provide further insight into the effects of icosapent ethyl on various biomarkers, as well as valuable information about higher loading doses of this drug.”

For more information about Amarin’s COVID-19 research, please visit the COVID-19 Related Materials section on Amarin’s publications page at https://investor.amarincorp.com/publications.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist